User menu

Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications.

Bibliographic reference Body, J-J ; Bergmann, P ; Boonen, S ; Devogelaer, Jean-Pierre ; Gielen, E ; et. al. Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications.. In: Osteoporosis International : with other metabolic bone diseases, Vol. 23 Suppl 1, p. S1-23 (2012)
Permanent URL http://hdl.handle.net/2078.1/124537
  1. Body J.-J., Bergmann P., Boonen S., Boutsen Y., Devogelaer J.-P., Goemaere S., Kaufman J.-M., Rozenberg S., Reginster J.-Y., Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club, 10.1007/s00198-010-1223-4
  2. BOONEN S., VANDERSCHUEREN D., GEUSENS P., BOUILLON R., Age-associated endocrine deficiencies as potential determinants of femoral neck (type II) osteoporotic fracture occurrence in elderly men, 10.1046/j.1365-2605.1997.00047.x
  3. Boonen S., Bischoff-Ferrari H. A., Cooper C., Lips P., Ljunggren O., Meunier P. J., Reginster J.-Y., Addressing the Musculoskeletal Components of Fracture Risk with Calcium and Vitamin D: A Review of the Evidence, 10.1007/s00223-005-0009-8
  4. BOONEN S., VANDERSCHUEREN D., HAENTJENS P., LIPS P., Calcium and vitamin D in the prevention and treatment of osteoporosis - a clinical update, 10.1111/j.1365-2796.2006.01655.x
  5. , Patient level pooled analysis of 68 500 patients from seven major vitamin D fracture trials in US and Europe, 10.1136/bmj.b5463
  6. Tang Benjamin MP, Eslick Guy D, Nowson Caryl, Smith Caroline, Bensoussan Alan, Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older: a meta-analysis, 10.1016/s0140-6736(07)61342-7
  7. Avenell A, Gillespie WJ, Gillespie LD, O’Connell D (2009) Vitamin D and vitamin D analogues for preventing fractures associated with involutional and post-menopausal osteoporosis. Cochrane Database Syst Rev CD000227
  8. Boonen Steven, Lips Paul, Bouillon Roger, Bischoff-Ferrari Heike A., Vanderschueren Dirk, Haentjens Patrick, Need for Additional Calcium to Reduce the Risk of Hip Fracture with Vitamin D Supplementation: Evidence from a Comparative Metaanalysis of Randomized Controlled Trials, 10.1210/jc.2006-1404
  9. Chung M, Balk EM, Brendel M et al (2009) Vitamin D and calcium: a systematic review of health outcomes. Evid Rep Technol Assess (Full Rep) 1–420
  10. Bostick R. M., Kushi L. H., Wu Y., Meyer K. A., Sellers T. A., Folsom A. R., Relation of Calcium, Vitamin D, and Dairy Food Intake to Ischemic Heart Disease Mortality among Postmenopausal Women, 10.1093/oxfordjournals.aje.a009781
  11. KNOX E, ISCHqMIC-HEART-DISEASE MORTALITY AND DIETARY INTAKE OF CALCIUM, 10.1016/s0140-6736(73)91808-4
  12. Iso H., Stampfer M. J., Manson J. E., Rexrode K., Hennekens C. H., Colditz G. A., Speizer F. E., Willett W. C., Prospective Study of Calcium, Potassium, and Magnesium Intake and Risk of Stroke in Women, 10.1161/01.str.30.9.1772
  13. Griffith L, The influence of dietary and nondietary calcium supplementation on blood pressure An updated metaanalysis of randomized controlled trials, 10.1016/s0895-7061(98)00224-6
  14. Wang L., Manson J. E., Buring J. E., Lee I-M., Sesso H. D., Dietary Intake of Dairy Products, Calcium, and Vitamin D and the Risk of Hypertension in Middle-Aged and Older Women, 10.1161/hypertensionaha.107.107821
  15. Dickinson HO, Nicolson DJ, Cook JV, Campbell F, Beyer FR, Ford GA, Mason J (2006) Calcium supplementation for the management of primary hypertension in adults. Cochrane Database Syst Rev CD004639
  16. Reid Ian R., Horne Anne, Mason Barbara, Ames Ruth, Bava Usha, Gamble Gregory D., Effects of Calcium Supplementation on Body Weight and Blood Pressure in Normal Older Women: A Randomized Controlled Trial, 10.1210/jc.2004-2205
  17. Govers M J, Van der Meet R, Effects of dietary calcium and phosphate on the intestinal interactions between calcium, phosphate, fatty acids, and bile acids., 10.1136/gut.34.3.365
  18. Denke MA, Fox MM, Schulte MC (1993) Short-term dietary calcium fortification increases fecal saturated fat content and reduces serum lipids in men. J Nutr 123:1047–1053
  19. Zemel MB, Shi H, Greer B, Dirienzo D, Zemel PC (2000) Regulation of adiposity by dietary calcium. FASEB J 14:1132–1138
  20. Reid Ian R, Mason Barbara, Horne Anne, Ames Ruth, Clearwater Judith, Bava Usha, Orr-Walker Brandon, Wu Fiona, Evans Margaret C, Gamble Gregory D, Effects of calcium supplementation on serum lipid concentrations in normal older women:, 10.1016/s0002-9343(01)01138-x
  21. Bostick R. M., Effect of Calcium Supplementation on Serum Cholesterol and Blood Pressure: A Randomized, Double-blind, Placebo-Controlled, Clinical Trial, 10.1001/archfami.9.1.31
  22. Heaney RP (2003) Normalizing calcium intake: projected population effects for body weight. J Nutr 133:268S–270S
  23. Parikh SJ, Yanovski JA (2003) Calcium intake and adiposity. Am J Clin Nutr 77:281–287
  24. Barr SI (2003) Increased dairy product or calcium intake: is body weight or composition affected in humans? The Journal of nutrition 133:245S–248S
  25. Trowman Rebecca, Dumville Jo C., Hahn Seokyung, Torgerson David J., A systematic review of the effects of calcium supplementation on body weight, 10.1079/bjn20051727
  26. Lanou Amy Joy, Barnard Neal D, Dairy and weight loss hypothesis: an evaluation of the clinical trials : Nutrition Reviews©, Vol. 66, No. 5, 10.1111/j.1753-4887.2008.00032.x
  27. Bolland M. J., Avenell A., Baron J. A., Grey A., MacLennan G. S., Gamble G. D., Reid I. R., Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis, 10.1136/bmj.c3691
  28. Bolland M. J, Barber P A., Doughty R. N, Mason B., Horne A., Ames R., Gamble G. D, Grey A., Reid I. R, Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial, 10.1136/bmj.39440.525752.be
  29. REID I. R., SCHOOLER B. A., HANNAN S. F., IBBERTSON H. K., THE ACUTE BIOCHEMICAL EFFECTS OF FOUR PROPRIETARY CALCIUM PREPARATIONS, 10.1111/j.1445-5994.1986.tb01147.x
  30. Foley Robert N., Collins Allan J., Ishani Areef, Kalra Philip A., Calcium-phosphate levels and cardiovascular disease in community-dwelling adults: The Atherosclerosis Risk in Communities (ARIC) Study, 10.1016/j.ahj.2008.05.016
  31. Vestergaard Peter, Mosekilde Leif, Fractures in Patients with Primary Hyperparathyroidism: Nationwide Follow-up Study of 1201 Patients, 10.1007/s00268-002-6589-9
  32. Jackson Rebecca D., LaCroix Andrea Z., Gass Margery, Wallace Robert B., Robbins John, Lewis Cora E., Bassford Tamsen, Beresford Shirley A.A., Black Henry R., Blanchette Patricia, Bonds Denise E., Brunner Robert L., Brzyski Robert G., Caan Bette, Cauley Jane A., Chlebowski Rowan T., Cummings Steven R., Granek Iris, Hays Jennifer, Heiss Gerardo, Hendrix Susan L., Howard Barbara V., Hsia Judith, Hubbell F. Allan, Johnson Karen C., Judd Howard, Kotchen Jane Morley, Kuller Lewis H., Langer Robert D., Lasser Norman L., Limacher Marian C., Ludlam Shari, Manson JoAnn E., Margolis Karen L., McGowan Joan, Ockene Judith K., O'Sullivan Mary Jo, Phillips Lawrence, Prentice Ross L., Sarto Gloria E., Stefanick Marcia L., Van Horn Linda, Wactawski-Wende Jean, Whitlock Evelyn, Anderson Garnet L., Assaf Annlouise R., Barad David, Calcium plus Vitamin D Supplementation and the Risk of Fractures, 10.1056/nejmoa055218
  33. Hsia J., Heiss G., Ren H., Allison M., Dolan N. C., Greenland P., Heckbert S. R., Johnson K. C., Manson J. E., Sidney S., Trevisan M., , Calcium/Vitamin D Supplementation and Cardiovascular Events, 10.1161/circulationaha.106.673491
  34. Wang T. J., Pencina M. J., Booth S. L., Jacques P. F., Ingelsson E., Lanier K., Benjamin E. J., D'Agostino R. B., Wolf M., Vasan R. S., Vitamin D Deficiency and Risk of Cardiovascular Disease, 10.1161/circulationaha.107.706127
  35. Autier Philippe, Vitamin D Supplementation and Total MortalityA Meta-analysis of Randomized Controlled Trials, 10.1001/archinte.167.16.1730
  36. Lewis Joshua R, Calver Janine, Zhu Kun, Flicker Leon, Prince Richard L, Calcium supplementation and the risks of atherosclerotic vascular disease in older women: Results of a 5-year RCT and a 4.5-year follow-up, 10.1002/jbmr.176
  37. Park Yikyung, Leitzmann Michael F., Subar Amy F., Hollenbeck Albert, Schatzkin Arthur, Dairy Food, Calcium, and Risk of Cancer in the NIH-AARP Diet and Health Study, 10.1001/archinternmed.2008.578
  38. Martinez ME, Willett WC (1998) Calcium, vitamin D, and colorectal cancer: a review of the epidemiologic evidence. Cancer Epidemiol Biomarkers Prev 7:163–168
  39. Wu K., Calcium Intake and Risk of Colon Cancer in Women and Men, 10.1093/jnci/94.6.437
  40. Cho E., Smith-Warner S. A., Spiegelman D., Beeson W. L., van den Brandt P. A., Colditz G. A., Folsom A. R., Fraser G. E., Freudenheim J. L., Giovannucci E., Goldbohm R. A., Graham S., Miller A. B., Pietinen P., Potter J. D., Rohan T. E., Terry P., Toniolo P., Virtanen M. J., Willett W. C., Wolk A., Wu K., Yaun S.-S., Zeleniuch-Jacquotte A., Hunter D. J., Dairy Foods, Calcium, and Colorectal Cancer: A Pooled Analysis of 10 Cohort Studies, 10.1093/jnci/djh185
  41. Shaukat Aasma, Scouras Nicole, Schunemann Holger J., Role of Supplemental Calcium in the Recurrence of Colorectal Adenomas: A Metaanalysis of Randomized Controlled Trials, 10.1111/j.1572-0241.2005.41220.x
  42. Bond John H., Polyp guideline: diagnosis, treatment, and surveillance for patients with colorectal polyps, 10.1111/j.1572-0241.2000.03434.x
  43. Wactawski-Wende Jean, Kotchen Jane Morley, Anderson Garnet L., Assaf Annlouise R., Brunner Robert L., O'Sullivan Mary Jo, Margolis Karen L., Ockene Judith K., Phillips Lawrence, Pottern Linda, Prentice Ross L., Robbins John, Rohan Thomas E., Sarto Gloria E., Sharma Santosh, Stefanick Marcia L., Van Horn Linda, Wallace Robert B., Whitlock Evelyn, Bassford Tamsen, Beresford Shirley A.A., Black Henry R., Bonds Denise E., Brzyski Robert G., Caan Bette, Chlebowski Rowan T., Cochrane Barbara, Garland Cedric, Gass Margery, Hays Jennifer, Heiss Gerardo, Hendrix Susan L., Howard Barbara V., Hsia Judith, Hubbell F. Allan, Jackson Rebecca D., Johnson Karen C., Judd Howard, Kooperberg Charles L., Kuller Lewis H., LaCroix Andrea Z., Lane Dorothy S., Langer Robert D., Lasser Norman L., Lewis Cora E., Limacher Marian C., Manson JoAnn E., Calcium plus Vitamin D Supplementation and the Risk of Colorectal Cancer, 10.1056/nejmoa055222
  44. Weingarten MA, Zalmanovici A, Yaphe J (2008) Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. Cochrane Database Syst Rev CD003548
  45. Shin M.-H., Intake of Dairy Products, Calcium, and Vitamin D and Risk of Breast Cancer, 10.1093/jnci/94.17.1301
  46. Lin Jennifer, Intakes of Calcium and Vitamin D and Breast Cancer Risk in Women, 10.1001/archinte.167.10.1050
  47. McCullough M. L., Dairy, Calcium, and Vitamin D Intake and Postmenopausal Breast Cancer Risk in the Cancer Prevention Study II Nutrition Cohort, 10.1158/1055-9965.epi-05-0611
  48. Larsson S. C, Bergkvist L., Wolk A., Long-term dietary calcium intake and breast cancer risk in a prospective cohort of women, 10.3945/ajcn.2008.26704
  49. Rodriguez C, McCullough ML, Mondul AM, Jacobs EJ, Fakhrabadi-Shokoohi D, Giovannucci EL, Thun MJ, Calle EE (2003) Calcium, dairy products, and risk of prostate cancer in a prospective cohort of United States men. Cancer Epidemiol Biomarkers Prev 12:597–603
  50. Mitrou Panagiota N., Albanes Demetrius, Weinstein Stephanie J., Pietinen Pirjo, Taylor Philip R., Virtamo Jarmo, Leitzmann Michael F., A prospective study of dietary calcium, dairy products and prostate cancer risk (Finland), 10.1002/ijc.22553
  51. Giovannucci Edward, Liu Yan, Platz Elizabeth A., Stampfer Meir J., Willett Walter C., Risk factors for prostate cancer incidence and progression in the health professionals follow-up study, 10.1002/ijc.22788
  52. Hedlund T. E., Stable expression of the nuclear vitamin D receptor in the human prostatic carcinoma cell line JCA-1: evidence that the antiproliferative effects of 1 alpha, 25-dihydroxyvitamin D3 are mediated exclusively through the genomic signaling pathway, 10.1210/en.137.5.1554
  53. Koh K A, Sesso H D, Paffenbarger R S, Lee I-M, Dairy products, calcium and prostate cancer risk, 10.1038/sj.bjc.6603475
  54. Chan June M., Pietinen Pirjo, Virtanen Mikko, Malila Nea, Tangrea Joseph, Albanes Demetrius, Virtamo Jarmo, 10.1023/a:1008947201132
  55. Rohrmann Sabine, Platz Elizabeth A., Kavanaugh Claudine J., Thuita Lucy, Hoffman Sandra C., Helzlsouer Kathy J., Meat and dairy consumption and subsequent risk of prostate cancer in a US cohort study, 10.1007/s10552-006-0082-y
  56. Curhan Gary C., Comparison of Dietary Calcium with Supplemental Calcium and Other Nutrients as Factors Affecting the Risk for Kidney Stones in Women, 10.7326/0003-4819-126-7-199704010-00001
  57. Curhan Gary C., Willett Walter C., Rimm Eric B., Stampfer Meir J., A Prospective Study of Dietary Calcium and Other Nutrients and the Risk of Symptomatic Kidney Stones, 10.1056/nejm199303253281203
  58. Curhan Gary C., Willett Walter C., Knight Eric L., Stampfer Meir J., Dietary Factors and the Risk of Incident Kidney Stones in Younger Women : Nurses' Health Study II, 10.1001/archinte.164.8.885
  59. Bihl Geoffrey, Meyers Anthony, Recurrent renal stone disease—advances in pathogenesis and clinical management, 10.1016/s0140-6736(01)05782-8
  60. Holick Michael F., Vitamin D Deficiency, 10.1056/nejmra070553
  61. Bischoff-Ferrari Heike A., Willett Walter C., Wong John B., Stuck Andreas E., Staehelin Hannes B., Orav E. John, Thoma Anna, Kiel Douglas P., Henschkowski Jana, Prevention of Nonvertebral Fractures With Oral Vitamin D and Dose Dependency : A Meta-analysis of Randomized Controlled Trials, 10.1001/archinternmed.2008.600
  62. Bischoff H.A., Borchers M., Gudat F., Duermueller U., Theiler R., Stähelin H.B., Dick W., 10.1023/a:1017535728844
  63. Demay Marie, Muscle: A Nontraditional 1,25-Dihydroxyvitamin D Target Tissue Exhibiting Classic Hormone-Dependent Vitamin D Receptor Actions, 10.1210/en.2003-1096
  64. Capiati D. A., Vazquez G., Boland R. L., Protein Kinase C α Modulates the Ca2+ Influx Phase of the Ca2+ Response to 1α,25-Dihydroxy-Vitamin-D3 in Skeletal Muscle Cells, 10.1055/s-2001-14950
  65. Dirks-Naylor AJ, Lennon-Edwards S (2011) The effects of vitamin D on skeletal muscle function and cellular signaling. J Steroid Biochem Mol Biol
  66. Venning G., Recent developments in vitamin D deficiency and muscle weakness among elderly people, 10.1136/bmj.330.7490.524
  67. Visser Marjolein, Deeg Dorly J. H., Lips Paul, Low Vitamin D and High Parathyroid Hormone Levels as Determinants of Loss of Muscle Strength and Muscle Mass (Sarcopenia): The Longitudinal Aging Study Amsterdam, 10.1210/jc.2003-030604
  68. Bischoff-Ferrari HA, Borchers M, Gudat F, Dürmüller U, Stähelin HB, Dick W, Vitamin D Receptor Expression in Human Muscle Tissue Decreases With Age, 10.1359/jbmr.2004.19.2.265
  69. Sato Yoshihiro, Iwamoto Jun, Kanoko Tomohiro, Satoh Kei, Low-Dose Vitamin D Prevents Muscular Atrophy and Reduces Falls and Hip Fractures in Women after Stroke: A Randomized Controlled Trial, 10.1159/000087203
  70. Snijder Marieke B., van Schoor Natasja M., Pluijm Saskia M. F., van Dam Rob M., Visser Marjolein, Lips Paul, Vitamin D Status in Relation to One-Year Risk of Recurrent Falling in Older Men and Women, 10.1210/jc.2006-0510
  71. Bischoff-Ferrari H A, Dawson-Hughes B, Staehelin H B, Orav J E, Stuck A E, Theiler R, Wong J B, Egli A, Kiel D P, Henschkowski J, Fall prevention with supplemental and active forms of vitamin D: a meta-analysis of randomised controlled trials, 10.1136/bmj.b3692
  72. Gilsanz Vicente, Kremer Arye, Mo Ashley O., Wren Tishya A. L., Kremer Richard, Vitamin D Status and Its Relation to Muscle Mass and Muscle Fat in Young Women, 10.1210/jc.2009-2309
  73. Annweiler C., Beauchet O., Berrut G., Fantino B., Bonnefoy M., Herrmann F. R., Schott A. M., Is there an association between serum 25-hydroxyvitamin D concentration and muscle strength among older women? Results from baseline assessment of the EPIDOS study, 10.1007/s12603-009-0013-1
  74. Gupta R, Sharma U, Gupta N, Kalaivani M, Singh U, Guleria R, Jagannathan NR, Goswami R (2010) Effect of cholecalciferol and calcium supplementation on muscle strength and energy metabolism in vitamin D-deficient Asian Indians: a randomized, controlled trial. Clin Endocrinol (Oxf) 73:445–451
  75. Zhu Kun, Austin Nicole, Devine Amanda, Bruce David, Prince Richard L., A Randomized Controlled Trial of the Effects of Vitamin D on Muscle Strength and Mobility in Older Women with Vitamin D Insufficiency : EFFECTS OF VITAMIN D ON MUSCLE STRENGTH AND MOBILITY, 10.1111/j.1532-5415.2010.03142.x
  76. Pfeifer M., Begerow B., Minne H. W., Suppan K., Fahrleitner-Pammer A., Dobnig H., Effects of a long-term vitamin D and calcium supplementation on falls and parameters of muscle function in community-dwelling older individuals, 10.1007/s00198-008-0662-7
  77. Stockton KA, Mengersen K, Paratz JD, Kandiah D, Bennell KL (2011) Effect of vitamin D supplementation on muscle strength: a systematic review and meta-analysis. Osteoporos Int 22:859–871
  78. Pilz S, Tomaschitz A, Drechsler C, Dekker JM, Marz W (2010) Vitamin D deficiency and myocardial diseases. Mol Nutr Food Res 54:1103–1113
  79. Tishkoff Daniel X., Nibbelink Karl A., Holmberg Kristina H., Dandu Loredana, Simpson Robert U., Functional Vitamin D Receptor (VDR) in the T-Tubules of Cardiac Myocytes: VDR Knockout Cardiomyocyte Contractility, 10.1210/en.2007-0805
  80. Schleithoff SS, Zittermann A, Tenderich G, Berthold HK, Stehle P, Koerfer R (2006) Vitamin D supplementation improves cytokine profiles in patients with congestive heart failure: a double-blind, randomized, placebo-controlled trial. Am J Clin Nutr 83:754–759
  81. Sugden J. A., Davies J. I., Witham M. D., Morris A. D., Struthers A. D., Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels, 10.1111/j.1464-5491.2007.02360.x
  82. Pittas Anastassios G., Lau Joseph, Hu Frank B., Dawson-Hughes Bess, The Role of Vitamin D and Calcium in Type 2 Diabetes. A Systematic Review and Meta-Analysis, 10.1210/jc.2007-0298
  83. Pilz Stefan, Tomaschitz Andreas, Ritz Eberhard, Pieber Thomas R., Vitamin D status and arterial hypertension: a systematic review, 10.1038/nrcardio.2009.135
  84. Giovannucci Edward, 25-Hydroxyvitamin D and Risk of Myocardial Infarction in MenA Prospective Study, 10.1001/archinte.168.11.1174
  85. Dobnig Harald, Independent Association of Low Serum 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Levels With All-Cause and Cardiovascular Mortality, 10.1001/archinte.168.12.1340
  86. Pilz S., Dobnig H., Fischer J. E., Wellnitz B., Seelhorst U., Boehm B. O., Marz W., Low Vitamin D Levels Predict Stroke in Patients Referred to Coronary Angiography, 10.1161/strokeaha.107.513655
  87. Pilz Stefan, März Winfried, Wellnitz Britta, Seelhorst Ursula, Fahrleitner-Pammer Astrid, Dimai Hans P., Boehm Bernhard O., Dobnig Harald, Association of Vitamin D Deficiency with Heart Failure and Sudden Cardiac Death in a Large Cross-Sectional Study of Patients Referred for Coronary Angiography, 10.1210/jc.2008-0784
  88. Messenger W, Nielson CM, Li H, Beer T, Barrett-Connor E, Stone K, Shannon J (2012) Serum and dietary vitamin D and cardiovascular disease risk in elderly men: a prospective cohort study. Nutr Metab Cardiovasc Dis. doi: 10.1016/j.numecd.2011.10.019
  89. Jassal Simerjot K., Chonchol Michel, von Mühlen Denise, Smits Gerard, Barrett-Connor Elizabeth, Vitamin D, Parathyroid Hormone, and Cardiovascular Mortality in Older Adults: The Rancho Bernardo Study, 10.1016/j.amjmed.2010.07.013
  90. Bhandari Simran K., Pashayan Shahe, Liu In Lu A., Rasgon Scott A., Kujubu Dean A., Tom Thomas Y., Sim John J., 25-Hydroxyvitamin D Levels and Hypertension Rates, 10.1111/j.1751-7176.2010.00408.x
  91. Burgaz Ann, Orsini Nicola, Larsson Susanna C, Wolk Alicja, Blood 25-hydroxyvitamin D concentration and hypertension: a meta-analysis : , 10.1097/hjh.0b013e32834320f9
  92. Pfeifer M., Effects of a Short-Term Vitamin D3 and Calcium Supplementation on Blood Pressure and Parathyroid Hormone Levels in Elderly Women, 10.1210/jc.86.4.1633
  93. Margolis K. L., Ray R. M., Van Horn L., Manson J. E., Allison M. A., Black H. R., Beresford S. A.A., Connelly S. A., Curb J. D., Grimm R. H., Kotchen T. A., Kuller L. H., Wassertheil-Smoller S., Thomson C. A., Torner J. C., , Effect of Calcium and Vitamin D Supplementation on Blood Pressure: The Women's Health Initiative Randomized Trial, 10.1161/hypertensionaha.108.114991
  94. Witham Miles D, Nadir M Adnan, Struthers Allan D, Effect of vitamin D on blood pressure: a systematic review and meta-analysis : , 10.1097/hjh.0b013e32832f075b
  95. Geleijnse J. M., Vitamin D and the Prevention of Hypertension and Cardiovascular Diseases: A Review of the Current Evidence, 10.1038/ajh.2010.199
  96. Mathieu Chantal, Vitamin D and the immune system: Getting it right, 10.1138/20110505
  97. Shoenfeld Netta, Amital Howard, Shoenfeld Yehuda, The effect of melanism and vitamin D synthesis on the incidence of autoimmune disease, 10.1038/ncprheum0989
  98. Hughes D. A., Norton R., Vitamin D and respiratory health, 10.1111/j.1365-2249.2009.04001.x
  99. Hyppönen Elina, Läärä Esa, Reunanen Antti, Järvelin Marjo-Riitta, Virtanen Suvi M, Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study, 10.1016/s0140-6736(01)06580-1
  100. Zipitis C S, Akobeng A K, Vitamin D supplementation in early childhood and risk of type 1 diabetes: a systematic review and meta-analysis, 10.1136/adc.2007.128579
  101. Brekke Hilde K, Ludvigsson Johnny, Vitamin D supplementation and diabetes-related autoimmunity in the ABIS study, 10.1111/j.1399-5448.2006.00223.x
  102. Pierrot-Deseilligny Charles, Clinical implications of a possible role of vitamin D in multiple sclerosis, 10.1007/s00415-009-5139-x
  103. Amital H., Szekanecz Z., Szucs G., Danko K., Nagy E., Csepany T., Kiss E., Rovensky J., Tuchynova A., Kozakova D., Doria A., Corocher N., Agmon-Levin N., Barak V., Orbach H., Zandman-Goddard G., Shoenfeld Y., Serum concentrations of 25-OH vitamin D in patients with systemic lupus erythematosus (SLE) are inversely related to disease activity: is it time to routinely supplement patients with SLE with vitamin D?, 10.1136/ard.2009.120329
  104. Cutolo Maurizio, Otsa Kati, Uprus Maria, Paolino Sabrina, Seriolo Bruno, Vitamin D in rheumatoid arthritis, 10.1016/j.autrev.2007.07.001
  105. Merlino Linda A., Curtis Jeffrey, Mikuls Ted R., Cerhan James R., Criswell Lindsey A., Saag Kenneth G., Vitamin D intake is inversely associated with rheumatoid arthritis: Results from the Iowa Women's Health Study, 10.1002/art.11434
  106. Fleet James C., Molecular actions of vitamin D contributing to cancer prevention, 10.1016/j.mam.2008.07.003
  107. Tretli S, Hernes E, Berg J P, Hestvik U E, Robsahm T E, Association between serum 25(OH)D and death from prostate cancer, 10.1038/sj.bjc.6604865
  108. Goodwin Pamela J., Ennis Marguerite, Pritchard Kathleen I., Koo Jarley, Hood Nicky, Prognostic Effects of 25-Hydroxyvitamin D Levels in Early Breast Cancer, 10.1200/jco.2008.20.0725
  109. International Agency for Research on Cancer (IARC) (2008) Vitamin D and Cancer. In Cancer IAfro (ed) IARC Working Group reports. World Health Organisation, Lyon, pp 1–221
  110. Garland Cedric F., Gorham Edward D., Mohr Sharif B., Grant William B., Giovannucci Edward L., Lipkin Martin, Newmark Harold, Holick Michael F., Garland Frank C., Vitamin D and prevention of breast cancer: Pooled analysis, 10.1016/j.jsbmb.2006.12.007
  111. Abbas S., Linseisen J., Slanger T., Kropp S., Mutschelknauss E. J., Flesch-Janys D., Chang-Claude J., Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer--results of a large case-control study, 10.1093/carcin/bgm240
  112. Manson JoAnn E., Mayne Susan T., Clinton Steven K., Vitamin D and Prevention of Cancer — Ready for Prime Time?, 10.1056/nejmp1102022
  113. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP (2007) Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 85:1586–1591
  114. Chlebowski Rowan T., Johnson Karen C., Kooperberg Charles, Pettinger Mary, Wactawski-Wende Jean, Rohan Tom, Rossouw Jacques, Lane Dorothy, O’Sullivan Mary Jo, Yasmeen Shagufta, Hiatt Robert A., Shikany James M., Vitolins Mara, Khandekar Janu, Hubbell F. Allan, Calcium Plus Vitamin D Supplementation and the Risk of Breast Cancer, 10.1093/jnci/djn360
  115. Helzlsouer K. J., , Overview of the Cohort Consortium Vitamin D Pooling Project of Rarer Cancers, 10.1093/aje/kwq119
  116. Souberbielle Jean-Claude, Body Jean-Jacques, Lappe Joan M., Plebani Mario, Shoenfeld Yehuda, Wang Thomas J., Bischoff-Ferrari Heike A., Cavalier Etienne, Ebeling Peter R., Fardellone Patrice, Gandini Sara, Gruson Damien, Guérin Alain P., Heickendorff Lene, Hollis Bruce W., Ish-Shalom Sofia, Jean Guillaume, von Landenberg Philipp, Largura Alvaro, Olsson Tomas, Pierrot-Deseilligny Charles, Pilz Stefan, Tincani Angela, Valcour Andre, Zittermann Armin, Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice, 10.1016/j.autrev.2010.06.009
  117. Pazianas M, Cooper C, Ebetino FH, Russell RG (2010) Long-term treatment with bisphosphonates and their safety in postmenopausal osteoporosis. Ther Clin Risk Manag 6:325–343
  118. Green Jonathan R., Rogers Michael J., Pharmacologic profile of zoledronic acid: A highly potent inhibitor of bone resorption, 10.1002/ddr.10071
  119. Papapoulos Socrates E., Cremers Serge C.L.M., Prolonged Bisphosphonate Release after Treatment in Children, 10.1056/nejmc062792
  120. McNicholl Diarmuid, Heaney Liam, The Safety of Bisphosphonate Use in Premenopausal Women on Corticosteroids, 10.2174/157488610790936178
  121. Thiébaud D., Sauty A., Burckhardt P., Leuenberger P., Sitzler L., Green J. R., Kandra A., Zieschang J., Palacios P. Ibarra de, An In Vitro and In Vivo Study of Cytokines in the Acute-Phase Response Associated with Bisphosphonates, 10.1007/s002239900353
  122. Sauty A., Pecherstorfer M., Zimmer-Roth I., Fioroni P., Juillerat L., Markert M., Ludwig H., Leuenberger P., Burckhardt P., Thiébaudi D., Interleukin-6 and tumor necrosis factor α levels after bisphosphonates treatment in vitro and in patients with malignancy, 10.1016/8756-3282(95)00448-3
  123. Hewitt R. E., Lissina A., Green A. E., Slay E. S., Price D. A., Sewell A. K., The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins, 10.1111/j.1365-2249.2005.02665.x
  124. Miller Paul D, Mcclung Michael R, Macovei Liviu, Stakkestad Jacob A, Luckey Marjorie, Bonvoisin Bernard, Reginster Jean-Yves, Recker Robert R, Hughes Claire, Lewiecki E Michael, Felsenberg Dieter, Delmas Pierre D, Kendler David L, Bolognese Michael A, Mairon Nicole, Cooper Cyrus, Monthly Oral Ibandronate Therapy in Postmenopausal Osteoporosis: 1-Year Results From the MOBILE Study : ONCE-MONTHLY ORAL IBANDRONATE, 10.1359/jbmr.050313
  125. Recker Robert R., Lewiecki E. Michael, Miller Paul D., Reiffel James, Safety of Bisphosphonates in the Treatment of Osteoporosis, 10.1016/j.amjmed.2008.12.004
  126. Thompson Keith, Rogers Michael J, Statins Prevent Bisphosphonate-Induced γ,δ-T-Cell Proliferation and Activation In Vitro, 10.1359/jbmr.0301230
  127. Srivastava Tarak, Haney Connie J, Alon Uri S, Atorvastatin May Have No Effect on Acute Phase Reaction in Children After Intravenous Bisphosphonate Infusion, 10.1359/jbmr.081016
  128. Reid David M, Devogelaer Jean-Pierre, Saag Kenneth, Roux Christian, Lau Chak-Sing, Reginster Jean-Yves, Papanastasiou Philemon, Ferreira Alberto, Hartl Florian, Fashola Taiwo, Mesenbrink Peter, Sambrook Philip N, Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial, 10.1016/s0140-6736(09)60250-6
  129. Bertoldo Francesco, Pancheri Serena, Zenari Sonia, Boldini Stefania, Giovanazzi Benedetta, Zanatta Mirko, Valenti Maria Teresa, Carbonare Luca Dalle, Cascio Vincenzo Lo, Serum 25-hydroxyvitamin D levels modulate the acute-phase response associated with the first nitrogen-containing bisphosphonate infusion, 10.1359/jbmr.090819
  130. Bock O, Boerst H, Thomasius FE, Degner C, Stephan-Oelkers M, Valentine SM, Felsenberg D (2007) Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact 7:144–148
  131. Black Dennis M., Delmas Pierre D., Eastell Richard, Reid Ian R., Boonen Steven, Cauley Jane A., Cosman Felicia, Lakatos Péter, Leung Ping Chung, Man Zulema, Mautalen Carlos, Mesenbrink Peter, Hu Huilin, Caminis John, Tong Karen, Rosario-Jansen Theresa, Krasnow Joel, Hue Trisha F., Sellmeyer Deborah, Eriksen Erik Fink, Cummings Steven R., Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis, 10.1056/nejmoa067312
  132. Caplan Liron, Pittman Cory B., Zeringue Angelique L., Scherrer Jeffrey F., Wehmeier Kent R., Cunningham Francesca E., Eisen Seth A., McDonald Jay R., An Observational Study of Musculoskeletal Pain Among Patients Receiving Bisphosphonate Therapy, 10.4065/mcp.2009.0492
  133. Miller Paul D, Roux Christian, Boonen Steven, Barton Ian P, Dunlap Lisa E, Burgio David E, Safety and Efficacy of Risedronate in Patients With Age-Related Reduced Renal Function as Estimated by the Cockcroft and Gault Method: A Pooled Analysis of Nine Clinical Trials, 10.1359/jbmr.050817
  134. Jamal Sophie A, Bauer Douglas C, Ensrud Kristine E, Cauley Jane A, Hochberg Marc, Ishani Areef, Cummings Steven R, Alendronate Treatment in Women With Normal to Severely Impaired Renal Function: An Analysis of the Fracture Intervention Trial, 10.1359/jbmr.070112
  135. Toussaint N. D., Elder G. J., Kerr P. G., Bisphosphonates in Chronic Kidney Disease; Balancing Potential Benefits and Adverse Effects on Bone and Soft Tissue, 10.2215/cjn.02550508
  136. Fan Stanley L.-S., Almond Michael K., Ball Elizabeth, Evans Kathy, Cunningham John, Pamidronate therapy as prevention of bone loss following renal transplantation1, 10.1046/j.1523-1755.2000.00890.x
  137. Coco M., Prevention of Bone Loss in Renal Transplant Recipients: A Prospective, Randomized Trial of Intravenous Pamidronate, 10.1097/01.asn.0000087092.53894.80
  138. Palmer SC, McGregor DO, Strippoli GF (2007) Interventions for preventing bone disease in kidney transplant recipients. Cochrane Database Syst Rev CD005015
  139. Shiraishi Naoki, Kitamura Kenichiro, Miyoshi Taku, Adachi Masataka, Kohda Yukimasa, Nonoguchi Hiroshi, Misumi Shuuko, Maekawa Yoshihiro, Murayama Toshihiko, Tomita Masao, Tomita Kimio, Successful Treatment of a Patient With Severe Calcific Uremic Arteriolopathy (Calciphylaxis) by Etidronate Disodium, 10.1053/j.ajkd.2006.04.062
  140. Monney P., Nguyen Q.-V., Perroud H., Descombes E., Rapid improvement of calciphylaxis after intravenous pamidronate therapy in a patient with chronic renal failure, 10.1093/ndt/gfh305
  141. Body Jean-Jacques, The Risk of Cumulative Renal Effects of Intravenous Bisphosphonates, 10.3816/sct.2006.n.002
  142. Bounameaux HenriM., Schifferli Jurg, Montani Jean-Pierre, Jung André, Chatelanat Francois, RENAL FAILURE ASSOCIATED WITH INTRAVENOUS DIPHOSPHONATES, 10.1016/s0140-6736(83)91465-4
  143. Ibrahim A, Scher N, Williams G et al (2003) Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. Clin Cancer Res 9:2394–2399
  144. Miller Paul D., The kidney and bisphosphonates, 10.1016/j.bone.2010.12.024
  145. Rey J, Daumen-Legre V, Pham T, Bernard P, Dahan L, Acquaviva PC, Lafforgue P (2000) Uveitis, an under-recognized adverse effect of pamidronate. Case report and literature review. Joint Bone Spine 67:337–340
  146. Malik A R, Bilateral acute anterior uveitis after alendronate, 10.1136/bjo.86.12.1443
  147. Durnian J M, Olujohungbe A, Kyle G, Bilateral acute uveitis and conjunctivitis after zoledronic acid therapy, 10.1038/sj.eye.6701461
  148. Fietta P, Clodronate induced uveitis, 10.1136/ard.62.4.378
  149. Fraunfelder Frederick W, Fraunfelder Frederick T, Jensvold Bree, Scleritis and other ocular side effects associated with pamidronate disodium, 10.1016/s0002-9394(02)01840-8
  150. Lufkin E. G., Argueta R., Whitaker M. D., Cameron A. L., Wong V. H., Egan K. S., O'Fallon W. M., Riggs B. L., Pamidronate: An unrecognized problem in gastrointestinal tolerability, 10.1007/bf01622190
  151. de Groen Piet C., Lubbe Dieter F., Hirsch Laurence J., Daifotis Anastasia, Stephenson Wendy, Freedholm Debra, Pryor-Tillotson Suzanne, Seleznick Mitchel J., Pinkas Haim, Wang Kenneth K., Esophagitis Associated with the Use of Alendronate, 10.1056/nejm199610033351403
  152. Cryer B., Miller P., Petruschke R. A., Chen E., Geba G. P., Papp A. E., Upper gastrointestinal tolerability of once weekly alendronate 70 mg with concomitant non-steroidal anti-inflammatory drug use, 10.1111/j.1365-2036.2005.02378.x
  153. Greenspan Susan, Field-Munves Ellen, Tonino Richard, Smith Mary, Petruschke Richard, Wang Lixia, Yates John, de Papp Anne E., Palmisano Joanne, Tolerability of Once-Weekly Alendronate in Patients With Osteoporosis: A Randomized, Double-Blind, Placebo-Controlled Study, 10.4065/77.10.1044
  154. Eisman J. A., Rizzoli R., Roman-Ivorra J., Lipschitz S., Verbruggen N., Gaines K. A., Melton M. E., Upper gastrointestinal and overall tolerability of alendronate once weekly in patients with osteoporosis: results of a randomized, double-blind, placebo-controlled study, 10.1185/030079904125003548
  155. Bobba Raja S, Beattie Karen, Parkinson Bill, Kumbhare Dinesh, Adachi Jonathan D, Tolerability of Different Dosing Regimens of Bisphosphonates for the Treatment of Osteoporosis and Malignant Bone Disease : , 10.2165/00002018-200629120-00005
  156. Cadarette S. M., Katz J. N., Brookhart M. A., Stürmer T., Stedman M. R., Levin R., Solomon D. H., Comparative gastrointestinal safety of weekly oral bisphosphonates, 10.1007/s00198-009-0871-8
  157. Rosen Clifford J, Hochberg Marc C, Bonnick Sydney L, McClung Michael, Miller Paul, Broy Susan, Kagan Risa, Chen Erluo, Petruschke Richard A, Thompson Desmond E, de Papp Anne E, Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study, 10.1359/jbmr.040920
  158. Vestergaard Peter, Schwartz Kristoffer, Pinholt Else Marie, Rejnmark Lars, Mosekilde Leif, Gastric and Esophagus Events Before and During Treatment of Osteoporosis, 10.1007/s00223-009-9323-x
  159. Cryer Byron, Bauer Douglas C., Oral Bisphosphonates and Upper Gastrointestinal Tract Problems: What Is the Evidence?, 10.4065/77.10.1031
  160. Green J., Czanner G., Reeves G., Watson J., Wise L., Beral V., Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort, 10.1136/bmj.c4444
  161. Cardwell Chris R., Abnet Christian C., Cantwell Marie M., Murray Liam J., Exposure to Oral Bisphosphonates and Risk of Esophageal Cancer, 10.1001/jama.2010.1098
  162. Nguyen Dang M., Schwartz Jim, Richardson Peter, El-Serag Hashem B., Oral Bisphosphonate Prescriptions and the Risk of Esophageal Adenocarcinoma in Patients with Barrett’s Esophagus, 10.1007/s10620-010-1198-1
  163. Lyles Kenneth W., Colón-Emeric Cathleen S., Magaziner Jay S., Adachi Jonathan D., Pieper Carl F., Mautalen Carlos, Hyldstrup Lars, Recknor Chris, Nordsletten Lars, Moore Kathy A., Lavecchia Catherine, Zhang Jie, Mesenbrink Peter, Hodgson Patricia K., Abrams Ken, Orloff John J., Horowitz Zebulun, Eriksen Erik Fink, Boonen Steven, Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture, 10.1056/nejmoa074941
  164. Cummings Steven R., Schwartz Ann V., Black Dennis M., Alendronate and Atrial Fibrillation, 10.1056/nejmc076132
  165. Karam R, Camm J, McClung M (2007) Yearly zoledronic acid in postmenopausal osteoporosis. N Engl J Med 357:712–713, author reply 714-715
  166. Lewiecki E. M., Cooper C., Thompson E., Hartl F., Mehta D., Papapoulos S. E., Ibandronate does not increase risk of atrial fibrillation in analysis of pivotal clinical trials, 10.1111/j.1742-1241.2010.02335.x
  167. Varma Raja, Aronow Wilbert S., Basis Yana, Singh Tarundit, Kalapatapu Kumar, Weiss Melvin B., Pucillo Anthony L., Monsen Craig E., Relation of Bone Mineral Density to Frequency of Coronary Heart Disease, 10.1016/j.amjcard.2007.12.013
  168. Choi Sung Hee, An Jee Hyun, Lim Soo, Koo Bo Kyung, Park Se Eun, Chang Hyuck Jae, Choi Sang Il, Park Young Joo, Park Kyong Soo, Jang Hak Chul, Shin Chan Soo, Lower bone mineral density is associated with higher coronary calcification and coronary plaque burdens by multidetector row coronary computed tomography in pre- and postmenopausal women, 10.1111/j.1365-2265.2009.03535.x
  169. Eriksen Erik Fink, Lyles Kenneth W, Colón-Emeric Cathleen S, Pieper Carl F, Magaziner Jay S, Adachi Jonathan D, Hyldstrup Lars, Recknor Chris, Nordsletten Lars, Lavecchia Catherine, Hu Huilin, Boonen Steven, Mesenbrink Peter, Antifracture Efficacy and Reduction of Mortality in Relation to Timing of the First Dose of Zoledronic Acid After Hip Fracture, 10.1359/jbmr.090209
  170. McCloskey EV, Yates AJ, Beneton MN, Galloway J, Harris S, Kanis JA (1987) Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone 8(Suppl 1):S35–41
  171. Brinkmeier Thomas, Kügler Katrin, Lepoittevin Jean-Pierre, Frosch Peter J., Adverse cutaneous drug reaction to alendronate, 10.1111/j.1600-0536.2006.01071.x
  172. Krasagakis Konstantin, Krüger-Krasagakis Sabine, Ioannidou Despina, Tosca Androniki, Chronic erosive and ulcerative oral lesions caused by incorrect administration of alendronate, 10.1016/j.jaad.2003.07.030
  173. Yanık B., Turkay C., Atalar H., Hepatotoxicity induced by alendronate therapy, 10.1007/s00198-007-0323-2
  174. Phillips Michael B., Risedronate-induced Hepatitis, 10.1016/j.amjmed.2006.04.032
  175. Coleman Robert, Cook Richard, Hirsh Vera, Major Pierre, Lipton Allan, Zoledronic acid use in cancer patients : More than just supportive care?, 10.1002/cncr.25529
  176. Gnant M, Clezardin P (2012) Direct and indirect anticancer activity of bisphosphonates: a brief review of published literature. Cancer Treat Rev (in press)
  177. Normanno Nicola, De Luca Antonella, Gallo Marianna, Lamura Luana, Perrone Francesco, Zoledronic acid in early-stage breast cancer, 10.1016/s1470-2045(11)70216-9
  178. Coleman Robert E., Marshall Helen, Cameron David, Dodwell David, Burkinshaw Roger, Keane Maccon, Gil Miguel, Houston Stephen J., Grieve Robert J., Barrett-Lee Peter J., Ritchie Diana, Pugh Julia, Gaunt Claire, Rea Una, Peterson Jennifer, Davies Claire, Hiley Victoria, Gregory Walter, Bell Richard, Breast-Cancer Adjuvant Therapy with Zoledronic Acid, 10.1056/nejmoa1105195
  179. Gnant Michael, Zoledronic acid in breast cancer: latest findings and interpretations, 10.1177/1758834011420599
  180. Zhao Xinmin, Xu Xiaofeng, Zhang Qunling, Jia Zhen, Sun Si, Zhang Jian, Wang Biyun, Wang Zhonghua, Hu Xichun, Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid, 10.1186/1471-2407-11-403
  181. Chlebowski RT, Col N (2011) Bisphosphonates and breast cancer prevention. Anticancer Agents Med Chem
  182. Rennert Gad, Pinchev Mila, Rennert Hedy S., Gruber Stephen B., Use of Bisphosphonates and Reduced Risk of Colorectal Cancer, 10.1200/jco.2010.33.7485
  183. Sassa S, Okabe H, Nemoto N, Kikuchi H, Kudo H, Sakamoto S (2009) Ibandronate may prevent colorectal carcinogenesis in mice with ulcerative colitis. Anticancer Res 29:4615–4619
  184. Kahn MF, Chamot AM (1992) SAPHO syndrome. Rheum Dis Clin North Am 18:225–246
  185. Kopterides Petros, Pikazis Dimitrios, Koufos Christos, Successful treatment of SAPHO syndrome with zoledronic acid, 10.1002/art.20464
  186. Siau Keith, Laversuch Catherine J., SAPHO syndrome in an adult with ulcerative colitis responsive to intravenous pamidronate: a case report and review of the literature, 10.1007/s00296-009-1021-5
  187. Codriansky Katerine A., Rünger Thomas M., Bhawan Jag, Kantarci Alpdogan, Kissin Eugene Y., Multicentric reticulohistiocytosis: A systemic osteoclastic disease?, 10.1002/art.23320
  188. King Melissa M., Nelson Douglas A., Hypertrophic Osteoarthropathy Effectively Treated with Zoledronic Acid, 10.3816/clc.2008.n.027
  189. Schonfeld SE (2010) Strategies for managing periodontal inflammation. J Calif Dent Assoc 38:272–283
  190. Braithwaite R. Scott, Chlebowski Rowan T., Lau Joseph, George Suzanne, Hess Rachel, Col Nananda F., Meta-analysis of vascular and neoplastic events associated with tamoxifen, 10.1046/j.1525-1497.2003.20724.x
  191. Bushnell C. D., Goldstein L. B., Risk of ischemic stroke with tamoxifen treatment for breast cancer: A meta-analysis, 10.1212/01.wnl.0000140491.54664.50
  192. Mosca L., Grady D., Barrett-Connor E., Collins P., Wenger N., Abramson B. L., Paganini-Hill A., Geiger M. J., Dowsett S. A., Amewou-Atisso M., Kornitzer M., Effect of Raloxifene on Stroke and Venous Thromboembolism According to Subgroups in Postmenopausal Women at Increased Risk of Coronary Heart Disease, 10.1161/strokeaha.108.518621
  193. Cummings Steven R., Ensrud Kristine, Delmas Pierre D., LaCroix Andrea Z., Vukicevic Slobodan, Reid David M., Goldstein Steven, Sriram Usha, Lee Andy, Thompson John, Armstrong Roisin A., Thompson David D., Powles Trevor, Zanchetta Jose, Kendler David, Neven Patrick, Eastell Richard, Lasofoxifene in Postmenopausal Women with Osteoporosis, 10.1056/nejmoa0808692
  194. Cuzick J., Forbes J. F., Sestak I., Cawthorn S., Hamed H., Holli K., Howell A., Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial, 10.1093/jnci/djk049
  195. Collins P., Mosca L., Geiger M. J., Grady D., Kornitzer M., Amewou-Atisso M. G., Effron M. B., Dowsett S. A., Barrett-Connor E., Wenger N. K., Effects of the Selective Estrogen Receptor Modulator Raloxifene on Coronary Outcomes in The Raloxifene Use for the Heart Trial: Results of Subgroup Analyses by Age and Other Factors, 10.1161/circulationaha.108.817577
  196. Adomaityte J, Farooq M, Qayyum R (2008) Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis Thromb Haemost 99:338–342
  197. Grady Deborah, Ettinger Bruce, Moscarelli Elena, Plouffe Leo, Sarkar Somnath, Ciaccia Angelina, Cummings Steven, Safety and Adverse Effects Associated With Raloxifene: Multiple Outcomes of Raloxifene Evaluation : , 10.1097/01.aog.0000137349.79204.b8
  198. Duvernoy Claire S., Yeo Adeline A., Wong Mayme, Cox David A., Kim Hyungjin M., Antiplatelet Therapy Use and the Risk of Venous Thromboembolic Events in the Raloxifene Use for the Heart (RUTH) Trial, 10.1089/jwh.2009.1687
  199. Ensrud K., LaCroix A., Thompson J. R., Thompson D. D., Eastell R., Reid D. M., Vukicevic S., Cauley J., Barrett-Connor E., Armstrong R., Welty F., Cummings S., Lasofoxifene and Cardiovascular Events in Postmenopausal Women With Osteoporosis: Five-Year Results From the Postmenopausal Evaluation and Risk Reduction With Lasofoxifene (PEARL) Trial, 10.1161/circulationaha.109.924571
  200. Barrett-Connor Elizabeth, Cauley Jane A, Kulkarni Pandurang M, Sashegyi Andreas, Cox David A, Geiger Mary Jane, Risk-Benefit Profile for Raloxifene: 4-Year Data From the Multiple Outcomes of Raloxifene Evaluation (MORE) Randomized Trial, 10.1359/jbmr.040406
  201. Grady D, Cauley JA, Stock JL, Cox DA, Mitlak BH, Song J, Cummings SR (2010) Effect of raloxifene on all-cause mortality. Am J Med 123(469):e461–467
  202. Vogel V. G., Costantino J. P., Wickerham D. L., Cronin W. M., Cecchini R. S., Atkins J. N., Bevers T. B., Fehrenbacher L., Pajon E. R., Wade J. L., Robidoux A., Margolese R. G., James J., Runowicz C. D., Ganz P. A., Reis S. E., McCaskill-Stevens W., Ford L. G., Jordan V. C., Wolmark N., , Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing Breast Cancer, 10.1158/1940-6207.capr-10-0076
  203. Martino S., Cauley J. A., Barrett-Connor E., Powles T. J., Mershon J., Disch D., Secrest R. J., Cummings S. R., , Continuing Outcomes Relevant to Evista: Breast Cancer Incidence in Postmenopausal Osteoporotic Women in a Randomized Trial of Raloxifene, 10.1093/jnci/djh319
  204. Vogel Victor G., Qu Yongming, Wong Mayme, Mitchell Beth, Mershon John L., Incidence of Invasive Breast Cancer in Postmenopausal Women After Discontinuation of Long-Term Raloxifene Administration, 10.3816/cbc.2009.n.008
  205. Grady D., Cauley J. A., Geiger M. J., Kornitzer M., Mosca L., Collins P., Wenger N. K., Song J., Mershon J., Barrett-Connor E., , Reduced Incidence of Invasive Breast Cancer With Raloxifene Among Women at Increased Coronary Risk, 10.1093/jnci/djn153
  206. LaCroix A. Z., Powles T., Osborne C. K., Wolter K., Thompson J. R., Thompson D. D., Allred D. C., Armstrong R., Cummings S. R., Eastell R., Ensrud K. E., Goss P., Lee A., Neven P., Reid D. M., Curto M., Vukicevic S., , Breast Cancer Incidence in the Randomized PEARL Trial of Lasofoxifene in Postmenopausal Osteoporotic Women, 10.1093/jnci/djq415
  207. Palacios Santiago, Lucia F. Farias Maria, Luebbert Horst, Gomez Gustavo, Yabur Juan A, Quail Deborah C, Turbi Carmen, Kayath Marcia J, Almeida Maria J, Mönnig Elisabeth, Nickelsen Thomas, Raloxifene is not associated with biologically relevant changes in hot flushes in postmenopausal women for whom therapy is appropriate, 10.1016/j.ajog.2003.10.701
  208. Gordon Stephen, Walsh Brian W., Ciaccia Angelina V., Siddhanti Suresh, Rosen Amy S., Plouffe Leo, Transition From Estrogen–Progestin to Raloxifene in Postmenopausal Women : Effect on Vasomotor Symptoms, 10.1097/01.aog.0000110247.98588.ff
  209. Davis Susan R., OʼNeill Sheila M., Eden John, Baber Rodney, Ekangaki Abie, Stocks Jodie M., Thiebaud Daniel, Transition from estrogen therapy to raloxifene in postmenopausal women: effects on treatment satisfaction and the endometrium—a pilot study : , 10.1097/01.gme.0000087981.28957.cf
  210. Utian Wulf, Yu Holly, Bobula Joel, Mirkin Sebastian, Olivier Sophie, Pickar James H., Bazedoxifene/conjugated estrogens and quality of life in postmenopausal women, 10.1016/j.maturitas.2009.06.006
  211. Marie P. J., Felsenberg D., Brandi M. L., How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis, 10.1007/s00198-010-1369-0
  212. Henrotin Y., Labasse A., Zheng S. X., Galais Ph., Tsouderos Y., Crielaard J. M., Reginster J. Y., Strontium Ranelate Increases Cartilage Matrix Formation, 10.1359/jbmr.2001.16.2.299
  213. Alexandersen Peter, Karsdal M.A., Qvist Per, Reginster J-Y., Christiansen Claus, Strontium ranelate reduces the urinary level of cartilage degradation biomarker CTX-II in postmenopausal women, 10.1016/j.bone.2006.07.028
  214. Alexandersen P., Karsdal M. A., Byrjalsen I., Christiansen C., Strontium ranelate effect in postmenopausal women with different clinical levels of osteoarthritis, 10.3109/13697137.2010.507887
  215. Bruyere O, Delferriere D, Roux C, Wark J D, Spector T, Devogelaer J-P, Brixen K, Adami S, Fechtenbaum J, Kolta S, Reginster J-Y, Effects of strontium ranelate on spinal osteoarthritis progression, 10.1136/ard.2007.075572
  216. European Medicines Agency (2009) Strontium ranelate. Summary of product characteristics, 3 June 2010. European Medicines Agency, London
  217. NÆSS I. A., CHRISTIANSEN S. C., ROMUNDSTAD P., CANNEGIETER S. C., ROSENDAAL F. R., HAMMERSTRØM J., Incidence and mortality of venous thrombosis: a population-based study, 10.1111/j.1538-7836.2007.02450.x
  218. Oger E (2000) Incidence of venous thromboembolism: a community-based study in Western France. EPI-GETBP Study Group Groupe d’Etude de la Thrombose de Bretagne Occidentale Thromb Haemost 83:657–660
  219. Silverstein Marc D., Heit John A., Mohr David N., Petterson Tanya M., O'Fallon W. Michael, Melton L. Joseph, Trends in the Incidence of Deep Vein Thrombosis and Pulmonary Embolism : A 25-Year Population-Based Study, 10.1001/archinte.158.6.585
  220. Breart G., Cooper C., Meyer O., Speirs C., Deltour N., Reginster J. Y., Osteoporosis and venous thromboembolism: a retrospective cohort study in the UK General Practice Research Database, 10.1007/s00198-009-1050-7
  221. Osborne Vicki, Layton Deborah, Perrio Michael, Wilton Lynda, Shakir Saad A.W., Incidence of Venous Thromboembolism in Users of Strontium Ranelate : An Analysis of Data from a Prescription-Event Monitoring Study in England, 10.2165/11533770-000000000-00000
  222. Breart G, Jakob FJ, Palacios S et al (2010) New interim analysis of a prospective observational cohort study of patients treated with strontium ranelate. Osteoporos Int S 1:S166
  223. Jonville-Béra A. P., Crickx B., Aaron L., Hartingh I., Autret-Leca E., Strontium ranelate-induced DRESS syndrome: first two case reports, 10.1111/j.1398-9995.2009.01940.x
  224. Lee H. Y., Lie D., Lim K. S., Thirumoorthy T., Pang S. M., Strontium ranelate-induced toxic epidermal necrolysis in a patient with post-menopausal osteoporosis, 10.1007/s00198-008-0677-0
  225. Pernicova I., Middleton E. T., Aye M., Rash, strontium ranelate and DRESS syndrome put into perspective. European Medicine Agency on the alert, 10.1007/s00198-008-0734-8
  226. Musette P., Brandi M. L., Cacoub P., Kaufman J. M., Rizzoli R., Reginster J.-Y., Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity, 10.1007/s00198-009-1097-5
  227. Penninger Josef M., Kong Young-Yun, Yoshida Hiroki, Sarosi Ildiko, Tan Hong-Lin, Timms Emma, Capparelli Casey, Morony Sean, Oliveira-dos-Santos Antonio J., Van Gwyneth, Itie Annick, Khoo Wilson, Wakeham Andrew, Dunstan Colin R., Lacey David L., Mak Tak W., Boyle William J., 10.1038/16852
  228. Baud’huin M., Lamoureux F., Duplomb L., Rédini F., Heymann D., RANKL, RANK, osteoprotegerin: key partners of osteoimmunology and vascular diseases, 10.1007/s00018-007-7104-0
  229. Ferrari-Lacraz S., Ferrari S., Do RANKL inhibitors (denosumab) affect inflammation and immunity?, 10.1007/s00198-010-1326-y
  230. Sobacchi Cristina, Frattini Annalisa, Guerrini Matteo M, Abinun Mario, Pangrazio Alessandra, Susani Lucia, Bredius Robbert, Mancini Grazia, Cant Andrew, Bishop Nick, Grabowski Peter, Del Fattore Andrea, Messina Chiara, Errigo Gabriella, Coxon Fraser P, Scott Debbie I, Teti Anna, Rogers Michael J, Vezzoni Paolo, Villa Anna, Helfrich Miep H, Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL, 10.1038/ng2076
  231. Ashcroft A.J, Cruickshank S.M, Croucher P.I, Perry M.J, Rollinson S, Lippitt J.M, Child J.A, Dunstan C, Felsburg P.J, Morgan G.J, Carding S.R, Colonic Dendritic Cells, Intestinal Inflammation, and T Cell-Mediated Bone Destruction Are Modulated by Recombinant Osteoprotegerin, 10.1016/s1074-7613(03)00326-1
  232. Cohen Stanley B., Dore Robin K., Lane Nancy E., Ory Peter A., Peterfy Charles G., Sharp John T., van der Heijde Désirée, Zhou Lifen, Tsuji Wayne, Newmark Richard, , Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial, 10.1002/art.23417
  233. Andrews NA (2008) Denosumab and the treatment of rheumatoid arthritis: in an occupied field, where will a RANKL inhibitor fit in? Bone Key 5:351–356
  234. Stolina Marina, Guo Jane, Faggioni Raffaella, Brown Heather, Senaldi Giorgio, Regulatory effects of osteoprotegerin on cellular and humoral immune responses, 10.1016/j.clim.2003.09.001
  235. Miller R. E., Branstetter D., Armstrong A., Kennedy B., Jones J., Cowan L., Bussiere J., Dougall W. C., Receptor Activator of NF- B Ligand Inhibition Suppresses Bone Resorption and Hypercalcemia but Does Not Affect Host Immune Responses to Influenza Infection, 10.4049/jimmunol.179.1.266
  236. McClung Michael R., Lewiecki E. Michael, Cohen Stanley B., Bolognese Michael A., Woodson Grattan C., Moffett Alfred H., Peacock Munro, Miller Paul D., Lederman Samuel N., Chesnut Charles H., Lain Douglas, Kivitz Alan J., Holloway Donna L., Zhang Charlie, Peterson Mark C., Bekker Pirow J., Denosumab in Postmenopausal Women with Low Bone Mineral Density, 10.1056/nejmoa044459
  237. Cummings Steven R., Martin Javier San, McClung Michael R., Siris Ethel S., Eastell Richard, Reid Ian R., Delmas Pierre, Zoog Holly B., Austin Matt, Wang Andrea, Kutilek Stepan, Adami Silvano, Zanchetta Jose, Libanati Cesar, Siddhanti Suresh, Christiansen Claus, Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis, 10.1056/nejmoa0809493
  238. Kendler David L, Roux Christian, Benhamou Claude Laurent, Brown Jacques P, Lillestol Michael, Siddhanti Suresh, Man Hoi-Shen, Martin Javier San, Bone Henry G, Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy, 10.1359/jbmr.090716
  239. Brown Jacques P, Prince Richard L, Deal Chad, Recker Robert R, Kiel Douglas P, de Gregorio Luiz H, Hadji Peyman, Hofbauer Lorenz C, Álvaro-Gracia Jose M, Wang Huei, Austin Matthew, Wagman Rachel B, Newmark Richard, Libanati Cesar, San Martin Javier, Bone Henry G, Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*, 10.1359/jbmr.0809010
  240. Miller Paul D., Wagman Rachel B., Peacock Munro, Lewiecki E. Michael, Bolognese Michael A., Weinstein Richard L., Ding Beiying, Martin Javier San, McClung Michael R., Effect of Denosumab on Bone Mineral Density and Biochemical Markers of Bone Turnover: Six-Year Results of a Phase 2 Clinical Trial, 10.1210/jc.2010-1805
  241. Bucay N., Sarosi I., Dunstan C. R., Morony S., Tarpley J., Capparelli C., Scully S., Tan H. L., Xu W., Lacey D. L., Boyle W. J., Simonet W. S., osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification, 10.1101/gad.12.9.1260
  242. Ziegler Sophie, Kudlacek Stefan, Luger Anton, Minar Erich, Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease, 10.1016/j.atherosclerosis.2005.01.042
  243. Mesquita Maria, Demulder Anne, Damry Nasroolla, Mélot Christian, Wittersheim Eric, Willems Dominique, Dratwa Max, Bergmann Pierre, Plasma osteoprotegerin is an independent risk factor for mortality and an early biomarker of coronary vascular calcification in chronic kidney disease, 10.1515/cclm.2009.075
  244. Kobayashi-Sakamoto Michiyo, Hirose Kimiharu, Isogai Emiko, Chiba Itsuo, NF-κB-dependent induction of osteoprotegerin by Porphyromonas gingivalis in endothelial cells, 10.1016/j.bbrc.2004.01.024
  245. Vik Anders, Mathiesen Ellisiv B., Notø Ann-Trude W., Sveinbjørnsson Baldur, Brox Jan, Hansen John-Bjarne, Serum osteoprotegerin is inversely associated with carotid plaque echogenicity in humans, 10.1016/j.atherosclerosis.2006.03.002
  246. Helas Susann, Goettsch Claudia, Schoppet Michael, Zeitz Ute, Hempel Ute, Morawietz Henning, Kostenuik Paul J., Erben Reinhold G., Hofbauer Lorenz C., Inhibition of Receptor Activator of NF-κB Ligand by Denosumab Attenuates Vascular Calcium Deposition in Mice, 10.2353/ajpath.2009.080957
  247. Hodsman Anthony B., Bauer Douglas C., Dempster David W., Dian Larry, Hanley David A., Harris Steven T., Kendler David L., McClung Michael R., Miller Paul D., Olszynski Wojciech P., Orwoll Eric, Yuen Chui Kin, Parathyroid Hormone and Teriparatide for the Treatment of Osteoporosis: A Review of the Evidence and Suggested Guidelines for Its Use, 10.1210/er.2004-0006
  248. Neer Robert M., Arnaud Claude D., Zanchetta Jose R., Prince Richard, Gaich Gregory A., Reginster Jean-Yves, Hodsman Anthony B., Eriksen Erik F., Ish-Shalom Sophia, Genant Harry K., Wang Ouhong, Mellström Dan, Oefjord Erik S., Marcinowska-Suchowierska Ewa, Salmi Jorma, Mulder Henk, Halse Johan, Sawicki Andrzej Z., Mitlak Bruce H., Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women with Osteoporosis, 10.1056/nejm200105103441904
  249. Hodsman Anthony B., Hanley David A., Ettinger Mark P., Bolognese Michael A., Fox John, Metcalfe Anna J., Lindsay Robert, Efficacy and Safety of Human Parathyroid Hormone-(1–84) in Increasing Bone Mineral Density in Postmenopausal Osteoporosis, 10.1210/jc.2003-030768
  250. Antoniucci Diana M., Sellmeyer Deborah E., Bilezikian John P., Palermo Lisa, Ensrud Kristine E., Greenspan Susan L., Black Dennis M., Elevations in Serum and Urinary Calcium with Parathyroid Hormone (1-84) with and without Alendronate for Osteoporosis, 10.1210/jc.2006-1788
  251. Winer Karen K., Sinaii Ninet, Reynolds James, Peterson Donna, Dowdy Karen, Cutler Gordon B., Long-Term Treatment of 12 Children with Chronic Hypoparathyroidism: A Randomized Trial Comparing Synthetic Human Parathyroid Hormone 1-34versusCalcitriol and Calcium, 10.1210/jc.2009-2464
  252. Winer K. K., A Randomized, Cross-Over Trial of Once-Daily Versus Twice-Daily Parathyroid Hormone 1-34 in Treatment of Hypoparathyroidism, 10.1210/jc.83.10.3480